“We are seeing a growing demand for integrated services. Customers prefer to have projects handled by a single provider, reducing time and complexity, while increasing accountability, especially for complex projects like antibody drug conjugation.”

Peter DeYoung, CEO, Piramal Pharma

“There are significant opportunities in long acting injectables, particularly in peptides. We are exploring the conversion of weight loss, antipsychotic and cancer therapies into once-a-month or once-every-three-month dosing regimens.”

Jay Shukla, President and CEO, Nivagen Pharmaceuticals

“Innovation comes from new flavors or integrating different active ingredients. We focus on stability, flavoring, and strong relationships with flavor houses to stay ahead.”

Jeff Reingold, COO, Contract Pharmacal Corp

“Our Research Triangle Park (RTP) storage facility offers multiple conditions from LN2 cryo-storage to walk-in cold and ultra-cold along with CRT pallet storage. Biologics continues to be a fast-growing segment, and our cold-chain storage capabilities are built for this growth.”

Timothy Compton, Chief Strategy Officer, Alcami

“There is growing interest in patient-centric dosage forms –long-acting injectables, nanomilling, engineered particles, PLGA microspheres, and implants (both bioerodible and biodurable). We are getting more interest in bioerodible implants, including intraocular and intraarticular administration.”

Robert W. Lee, Senior Vice President BD, Particle Sciences